ADA 2017 Hypoglycemia and role glycemic variability

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.

An assessment into development scores before, during and after the COVID-19 pandemic show children aged 0 - 5 years old may only had been minimally impacted in communication and problem-solving skills.

Medicaid registry data show parents and guardians whose children have been referred to CPS are more than 3-fold likely to have a substance use disorder.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.